AIM: To examine the effects of anisomycin on glioma cells and the related mechanisms in vitro. METHODS: The U251 and U87 human glioblastoma cell lines were tested. The growth of the cells was analyzed using a CCK-8 cell viability assay. Apoptosis was detected using a flow cytometry assay. The expression of proteins and phosphorylated kinases was detected using Western blotting. RESULTS: Treatment of U251 and U87 cells with anisomycin (0.01-8 μmol/L) inhibited the cell growth in time- and concentration-dependent manners (the IC(50) values at 48 h were 0.233±0.021 and 0.192±0.018 μmol/L, respectively). Anisomycin (4 μmol/L) caused 21.5%±2.2% and 25.3%±3.1% of apoptosis proportion, respectively, in U251 and U87 cells. In the two cell lines, anisomycin (4 μmol/L) activated p38 MAPK and JNK, and inactivated ERK1/2. However, neither the p38 MAPK inhibitor SB203580 (10 μmol/L) nor the JNK inhibitor SP600125 (10 μmol/L) prevented anisomycin-induced cell death. On the other hand, anisomycin (4 μmol/L) reduced the level of PP2A/C subunit (catalytic subunit) in a time-dependent manner in the two cell lines. Treatment of the two cell lines with the PP2A inhibitor okadaic acid (100 nmol/L) caused marked cell death. CONCLUSION: Anisomycin induces glioma cell death via down-regulation of PP2A catalytic subunit. The regulation of PP2A/C exression by anisomycin provides a clue to further study on its role in glioma therapy.
AIM: To examine the effects of anisomycin on glioma cells and the related mechanisms in vitro. METHODS: The U251 and U87 humanglioblastoma cell lines were tested. The growth of the cells was analyzed using a CCK-8 cell viability assay. Apoptosis was detected using a flow cytometry assay. The expression of proteins and phosphorylated kinases was detected using Western blotting. RESULTS: Treatment of U251 and U87 cells with anisomycin (0.01-8 μmol/L) inhibited the cell growth in time- and concentration-dependent manners (the IC(50) values at 48 h were 0.233±0.021 and 0.192±0.018 μmol/L, respectively). Anisomycin (4 μmol/L) caused 21.5%±2.2% and 25.3%±3.1% of apoptosis proportion, respectively, in U251 and U87 cells. In the two cell lines, anisomycin (4 μmol/L) activated p38MAPK and JNK, and inactivated ERK1/2. However, neither the p38MAPK inhibitor SB203580 (10 μmol/L) nor the JNK inhibitor SP600125 (10 μmol/L) prevented anisomycin-induced cell death. On the other hand, anisomycin (4 μmol/L) reduced the level of PP2A/C subunit (catalytic subunit) in a time-dependent manner in the two cell lines. Treatment of the two cell lines with the PP2A inhibitor okadaic acid (100 nmol/L) caused marked cell death. CONCLUSION:Anisomycin induces glioma cell death via down-regulation of PP2A catalytic subunit. The regulation of PP2A/C exression by anisomycin provides a clue to further study on its role in glioma therapy.
Authors: Xiaohua He; Jeffrey C Anderson; Olga del Pozo; Yong-Qiang Gu; Xiaoyan Tang; Gregory B Martin Journal: Plant J Date: 2004-05 Impact factor: 6.417
Authors: David M Ashley; Christopher D Riffkin; Andrea M Muscat; Melissa J Knight; Andrew H Kaye; Ulrike Novak; Christine J Hawkins Journal: Cancer Date: 2005-10-01 Impact factor: 6.860
Authors: P Lunghi; A Tabilio; S Pinelli; G Valmadre; E Ridolo; R Albertini; C Carlo-Stella; P P Dall'Aglio; P G Pelicci; A Bonati Journal: Hematol J Date: 2001
Authors: Imtiaz A Mawji; Craig D Simpson; Marcela Gronda; Moyo A Williams; Rose Hurren; Clare J Henderson; Alessandro Datti; Jeffrey L Wrana; Aaron D Schimmer Journal: Cancer Res Date: 2007-09-01 Impact factor: 12.701
Authors: Imtiaz A Mawji; Craig D Simpson; Rose Hurren; Marcela Gronda; Moyo A Williams; Jorge Filmus; James Jonkman; Ralph S Da Costa; Brian C Wilson; Michael P Thomas; John C Reed; Gennadi V Glinsky; Aaron D Schimmer Journal: J Natl Cancer Inst Date: 2007-05-16 Impact factor: 13.506
Authors: Ada J Kwong; Thao N D Pham; Hannah E Oelschlager; Hidayatullah G Munshi; Karl A Scheidt Journal: ACS Med Chem Lett Date: 2021-09-15 Impact factor: 4.632